IC BIOSOLUTIONS

IC BIOSOLUTIONS is a French biotech company developing a new class of acellular biological therapies based on secretomes derived from induced pluripotent stem cells (iPSCs). Its platform enables the production of standardized, safe, and scalable biomedicines designed to modulate inflammation and promote tissue regeneration. Its lead product, ICB001, is currently in regulated clinical development for the treatment of lameness associated with non-septic joint disorders in horses.
Beyond this initial indication, IC BIOSOLUTIONS aims to expand its technology to other veterinary applications, particularly in companion animals, and, in the longer term, to human health. The company is built on an innovative bioproduction approach, with the ambition to redefine the standards of regenerative therapies.